HUTCHMED (China) Limited (HK:0013) has released an update.
HUTCHMED (China) Limited, a commercial-stage biopharmaceutical company, has announced its total voting rights with 871,359,720 ordinary shares, each with one vote and none held in treasury. Shareholders can use this number to assess changes in their stake according to the Financial Conduct Authority’s rules. HUTCHMED specializes in developing targeted therapies for cancer and immunological diseases and is expanding its global reach.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
